HLA-B and hereditary disease: In addition, to the best of our knowledge, none of the previous studies of HLA-B AF in Arab countries (Williams et al., 2001; Elbjeirami et al., 2013; Hajjej et al., 2015; Ikhtiar et al., 2018; Ameen et al., 2020; Jawdat et al., 2020) investigated or reported pharmacogenomic data pertaining to genetic markers for genetic disorders, such as drug hypersensitivity.